Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples

Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples - Cross-reactivity analysis against recombinant porcine FVIII using Japanese acquired hemophilia A patients' plasma samples

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048635

Enrollment

Registered

2022-08-09

Start date

2022-08-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Hemophilia A

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The plasma samples of patients with AHA who were diagnosed and the informed consent was obtained from in the form of opt-out at Nara Medical University

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Cross-reacting against rpFVIII in acquired hemophilia A	—

Countries

Japan

Contacts

Public ContactYasuo Miyaguchi

Takeda Pharmaceutical Company Limited. Japan Medical Office

yasuo.miyaguchi@takeda.com070-4921-7966

Outcome results